Shuttle Pharmaceuticals Holdings, Inc. · NASDAQ:SHPH
Shuttle Pharmaceuticals — Investor Presentation (September 2024)
18 slides from Shuttle Pharmaceuticals's investor presentation, September 2024
Slide 1: Shuttle Pharmaceuticals Holdings, Inc. Investor Presentation Fall 2024
Shuttle Pharmaceuticals Holdings, Inc. Nasdaq: SHPH Investor Presentation Fall 2024
Slide 2: Forward Looking Statements
Forward Looking Statements All of the information contained within this business presentation (the “Presentation”) has been obtained from sources generally believed to be reliable by Shuttle Pharmaceuticals Holdings, Inc. (referred to herein as “Shuttle Pharmaceuticals,” “Shuttle Pharma” or the “Com
Slide 3: The Fundamental Problem of Radiation Therapy
The Fundamental Problem of Radiation Therapy: Cancers are surrounded by radiation sensitive, dose-limiting normal tissues Sensitization of cancer cells to radiation therapy The radiation dose determines cancer curability Adjacent normal tissues are dose-limiting Sensitizer Radiation sensitizer
Slide 4: Company Overview
Company Overview Shuttle Pharma (Nasdaq: SHPH) is a clinical-stage pharmaceutical company, developing next generation drugs and diagnostics to improve outcomes for cancer patients treated with radiation therapy (RT). Therapeutics Ropidoxuridine is a clinical stage, orally-administered cancer radia
Slide 5: Therapeutics – How does Ropidoxuridine (IPdR) work?
Therapeutics – How does Ropidoxuridine (IPdR) work? Ropidoxuridine (IPdR) is the prodrug of IUdR, a powerful radiation sensitizer. Mechanism Following oral administration, IPdR is converted to IUdR. Ropidoxuridine (IPdR) is metabolized to IUdR improved clinical outcomes for patients with brain tum
Slide 6: Ropidoxuridine (IPdR) – Clinical Asset Development
Ropidoxuridine (IPdR) – Clinical Asset Development Phase II study of Ropidoxuridine + RT in IDH wild-type, methylation negative glioblastoma patients. IND has been approved and the FDA has issued a safe to proceed letter. TCG GreenChem manufactured API, University of Iowa Pharmaceuticals formu
Slide 7: Therapeutics: Development of Selective HDAC Inhibitors
Therapeutics: Development of Selective HDAC Inhibitors Therapeutic Pipeline includes histone deacetylase inhibitors for post-RT Mechanism immune stimulation (SP-2-225) and treatment of ER+ breast cancers. HDAC inhibitors Acetylated Shuttle Pharma has discovered novel HDAC inhibitors using propriet
Slide 8: Therapeutics: Selective HDAC6 Inhibition with SP-2-225
Therapeutics: Selective HDAC6 Inhibition with SP-2-225 SP-2-225 inhibits HDAC6, prolongs macrophage polarization in M-1 state, resulting in an enhanced inflammatory response to immunogenic cancers and Acetylated histones Irradiated tumors. Active transcription The next step is to perform IND- enabli
Slide 9: Therapeutics: Clinical and Pre-clinical Development Strategies
Therapeutics: Clinical and Pre-clinical Development Strategies Clinical development of Ropidoxuridine & RT Perform the Phase II clinical trial of Ropidoxuridine & RT in brain tumors Seek FDA “breakthrough” designation and early marketing approval on glioblastoma Prepare Ropidoxuridine & RT r
Slide 10: Diagnostics: Clinical Validation of the PC-Rad Test
Diagnostics : Clinical Validation of the PC-Rad Test PC-Rad Test Kit Components Market Opportunity: Predictive biomarkers for prostate cancers • Calibrants for standard vials/ metabolomics and lipidomics ~ 268,000 new prostate cancer cases annually in the U.S. (incidence) • QC and internal stand
Slide 11: Theranostics/Diagnostics: Product Development – PSMA-B
Theranostics/Diagnostics: Product Development – PSMA-B The prostate-specific membrane antigen (PSMA) is located on the outside of prostate cancer cells. The PSMA ligand binds to PSMA, dimerizes, and is internalized into the cell. Diagnostic molecules for PET scanning are created by attaching radiois
Slide 12: Theranostics: PSMA-B ligand for diagnosis and treatment
Theranostics: PSMA-B ligand for diagnosis and treatment PET Scan Market Opportunity: PSMA imaging and therapy Widely metastatic prostate cancer The Global PSMA PET Imaging Market reached $ 1.5 billion in 2022 and is expected to reach $ 2.0 billion by 2030. Pluvicto (¹⁷⁷Lu-PSMA-617), a targeted r
Slide 13: Intellectual Property
Intellectual Property Ropidoxuridine (radiation sensitizers) Orphan disease designation, method of use patent for next generation IPdR/TPI formulation, manufacturing patents. Selective HDAC inhibitors (radiation sensitizers/immune modulators) > 20 composition of matter HDAC inhibitor patents in
Slide 14: Clinical Development Strategy for Shuttle Diagnostics
Clinical Development Strategy for Shuttle Diagnostics Develop the PC-Rad Test intellectual property as a predictive diagnostics test Predictive Biomarker for Prostate Cancer Establish and validate the predictive assay in the context of use (COU) for FDA approval. Perform a muti-institutional cli
Slide 15: Financial Overview
Financial Overview Shuttle Pharmaceuticals Capital Market Profile Cap Table as of June 30, 2024 Common Stock 2,026,838 Exchange/Ticker NASDAQ: SHPH Fully Vested Restricted Stock Units (RSUs) 79,395 Closing Stock Price* $1.76 RSUs Outstanding 58,839 52 Wk High/Low* $1.28 - $5.76 Warrants Outstanding
Slide 16: Shuttle's Experienced Leadership Team
Shuttle’s Experienced Leadership Team Founder & CEO of Shuttle President & COO of VP Regulatory Pharma since 2012; Chairman, Shuttle Pharma 2012 Shuttle Pharma 2012 Board of Directors 2017 CFO Shuttle Pharma CFO Shuttle Pharma Former Member, Board of 2012-2019 2019 - 2024 Directors, Neop
Slide 17: Board of Directors
Board of Directors Steve Richards, MBA, CPA Milton Brown, MD, PhD Bette Jacobs, PhD Chris Senanayake, PhD Joshua Schafer, MBA Chief Commercial Officer Businessman Vice Dean for Research Professor/Distinguished Scholar CEO, TCG GreenChem & EVP of Business Development CEO, Endurance Media East Virgini
Slide 18: Thank You
THANK YOU Shuttle Pharmaceuticals Holdings, Inc. Anatoly Dritschilo, MD, CEO Tel: (240) 403-1212 Email: anatoly.dritschilo@ShuttlePharma.org Investor Relations Lytham Partners Robert Blum Tel: (602) 889-9700 Email: SHPH@LythamPartners.com
Shuttle Pharmaceuticals Holdings — Investor Presentation (September 2024) on 6ix